News / Taiwan / economic_daily
Al-Biomed to List on Go Incubation Board for Startup Firms on Sept 23
Health Technology · Biotechnology · economic_daily · 2026-09-20
7437
Biotech firm Al-Biomed will join the Go Incubation Board on September 23, focusing on innovative drug delivery platforms for Alzheimer's and eye diseases.
What Happened
Market Entry: The Taipei Exchange has announced that Al-Biomed will list on the Go Incubation Board for Startup Firms on September 23. Founded in 2025, the company specializes in the R&D and commercialization of innovative drug delivery systems.
Core Technology: Al-Biomed focuses on Transdermal Drug Delivery Systems (TDDS) and non-invasive posterior segment drug delivery. Utilizing a 505(b)(2) development strategy, the company aims to enhance the efficacy and convenience of existing pharmaceutical products.
R&D Progress: The company is currently developing a seven-day long-acting transdermal patch for Alzheimer's disease to improve patient compliance. Additionally, its eye delivery technology aims to replace invasive ocular injections with non-invasive eye drops, targeting the high-potential retinal disease market.
Market Potential: With its proprietary technologies, Al-Biomed demonstrates strong R&D capabilities and competitive potential. By transforming traditional treatment methods, the company seeks to provide high-value clinical alternatives to the global healthcare market.